Twist Bioscience Corp TWST

About Twist Bioscience Corp (TWST): stock profile, AI score and financials

Twist Bioscience Corp (TWST) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TWST at 34.2/100 on a composite quality score built from its SEC filings, placing it at rank #2,345 of 2,925 stocks — the bottom half of the AI-ranked universe. TWST scores in the top quartile across revenue growth (81.5). Areas of concern include balance sheet strength (10.8) and profitability (12.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 10.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q3 2026), Twist Bioscience Corp reports quarterly revenue of $118.4M, net income of $-35.1M, an operating margin of -30.6%. Top institutional holders of TWST by reported 13-F value include BlackRock, Artisan Partners Limited Partnership, FMR, based on the most recent SEC filings. TWST trades on the Nasdaq exchange and files with the SEC under CIK 1581280. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TWST daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Twist Bioscience Corp directly from SEC EDGAR.

Financials through the period ended Jun 30, 2026SEC EDGAR: CIK 1581280 →